Two major drug companies are the latest to join TrumpRx⁠90%

By Edward Lawrence⁠87%

3/13/2026, 4:17:39 PM

BS Summary: This article contains 17 faulty reasoning types, including Confirmation Bias, Anchoring Bias, and Post Hoc (False Cause), with Framing Effect as the most egregious example at 82.7% saturation with 296 hits. Analysis detected 1,088 faulty-reasoning hits from 371 analyzed words, generating a BS Score of 83.4% and a BS Rank of ⁠90% (2,239 of 21,887 articles). This article is worse (more manipulative) than 89.80% of the article peer group.

EXCLUSIVE: The White House is expecting to announce an expansion of drugmakers offering discounts on TrumpRx.gov, FOX Business has learned. 
As early as today, Amgen and GSK will be added to the list of prescription drug manufacturers offering discounts on the government website. 
That makes a total of 54 prescription medications from six pharmaceutical companies that have signed on to the most-favored-nation pricing under pressure from President Donald Trump and the threat of tariffs. 
Amgen will offer medication on the website that cuts 80% off the retail price. 
Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. 
The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. 
FOX NEWS POLL: VOTERS SOUND ALARM ON HEALTHCARE COSTS 
The company plans to list Aimovig and Repatha for discounts of 62%. 
GSK will discount Incruse at 55% of the retail price. 
The drug treats COPD and will be listed at $159. 
GSK also plans to list Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. 
"GSK and Amgen connecting with TrumpRx.gov to offer prescription drugs directly to consumers at most-favored-nations pricing marks another milestone for President Trump’s affordability push," White House spokesman Kush Desai told FOX Business. 
"TrumpRx.gov is just the beginning, however, as Americans are set to (receive) even greater drug pricing discounts, lower insurance premiums and more transparency when Congress passes President Trump’s Great Healthcare Plan." 
The Pharmaceutical Research and Manufacturers of America represents major drug companies. 
CEO Stephen Ubl believes "Government-imposed most-favored-nation policies would undermine U.S. competitiveness while doing nothing to address insurance practices that deny care and raise costs for patients." 
"These policies would siphon billions from American R&D, slow the pace of cures and increase reliance on China for future innovation." 
The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. 
GET FOX BUSINESS ON THE GO BY CLICKING HERE 
Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. 
Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026. 
Article reasoning-pattern comparisonThis article: 50.8%Edward Lawrence: 7.9%FoxBusiness: 4.4%Confirmation Bias50.8%This article: 24.0%Edward Lawrence: 3.3%FoxBusiness: 3.4%Anchoring Bias24.0%This article: 0.0%Edward Lawrence: 1.0%FoxBusiness: 4.1%Availability Heuristic0.0%This article: 0.0%Edward Lawrence: 0.4%FoxBusiness: 1.1%Representativeness Heuristic0.0%This article: 0.0%Edward Lawrence: 0.7%FoxBusiness: 0.7%Hindsight Bias0.0%This article: 0.0%Edward Lawrence: 7.6%FoxBusiness: 3.7%Overconfidence Bias0.0%This article: 82.7%Edward Lawrence: 19.4%FoxBusiness: 12.9%Framing Effect82.7%This article: 13.1%Edward Lawrence: 1.0%FoxBusiness: 1.5%Loss Aversion13.1%This article: 0.0%Edward Lawrence: 0.4%FoxBusiness: 1.1%Status Quo Bias0.0%This article: 0.0%Edward Lawrence: 0.0%FoxBusiness: 0.2%Sunk Cost Effect0.0%This article: 14.0%Edward Lawrence: 5.9%FoxBusiness: 8.8%Optimism Bias14.0%This article: 5.9%Edward Lawrence: 2.1%FoxBusiness: 2.0%Pessimism Bias5.9%This article: 0.0%Edward Lawrence: 7.4%FoxBusiness: 7.9%Negativity Bias0.0%This article: 16.2%Edward Lawrence: 4.0%FoxBusiness: 4.5%Self-Serving Bias16.2%This article: 0.0%Edward Lawrence: 1.1%FoxBusiness: 0.9%Fundamental Attribution Error0.0%This article: 0.0%Edward Lawrence: 0.2%FoxBusiness: 0.2%Actor-Observer Bias0.0%This article: 0.0%Edward Lawrence: 1.3%FoxBusiness: 1.7%In-Group Bias0.0%This article: 0.0%Edward Lawrence: 0.8%FoxBusiness: 0.8%Out-Group Homogeneity Bias0.0%This article: 0.0%Edward Lawrence: 2.5%FoxBusiness: 3.8%Halo Effect0.0%This article: 0.0%Edward Lawrence: 0.7%FoxBusiness: 0.1%Horn Effect0.0%This article: 0.0%Edward Lawrence: 0.0%FoxBusiness: 0.0%Dunning-Kruger Effect0.0%This article: 0.0%Edward Lawrence: 1.7%FoxBusiness: 2.3%Recency Bias0.0%This article: 0.0%Edward Lawrence: 0.6%FoxBusiness: 0.4%Primacy Effect0.0%This article: 0.0%Edward Lawrence: 0.0%FoxBusiness: 0.1%Blind-Spot Bias0.0%This article: 0.0%Edward Lawrence: 0.8%FoxBusiness: 0.8%Ad Hominem0.0%This article: 7.3%Edward Lawrence: 0.2%FoxBusiness: 0.4%Straw Man7.3%This article: 8.9%Edward Lawrence: 5.8%FoxBusiness: 7.2%Appeal to Authority8.9%This article: 12.6%Edward Lawrence: 2.4%FoxBusiness: 1.6%False Dilemma12.6%This article: 14.5%Edward Lawrence: 2.2%FoxBusiness: 1.2%Slippery Slope14.5%This article: 0.0%Edward Lawrence: 0.6%FoxBusiness: 0.2%Circular Reasoning0.0%This article: 5.9%Edward Lawrence: 4.7%FoxBusiness: 6.3%Hasty Generalization5.9%This article: 2.5%Edward Lawrence: 0.3%FoxBusiness: 0.8%Red Herring2.5%This article: 0.0%Edward Lawrence: 1.2%FoxBusiness: 1.2%Bandwagon0.0%This article: 5.9%Edward Lawrence: 5.7%FoxBusiness: 6.1%Appeal to Emotion5.9%This article: 8.7%Edward Lawrence: 2.0%FoxBusiness: 1.2%Begging the Question8.7%This article: 19.8%Edward Lawrence: 6.2%FoxBusiness: 4.4%Post Hoc (False Cause)19.8%This article: 0.0%Edward Lawrence: 0.0%FoxBusiness: 0.1%Tu Quoque0.0%This article: 0.0%Edward Lawrence: 0.7%FoxBusiness: 0.4%Burden of Proof0.0%This article: 0.0%Edward Lawrence: 0.0%FoxBusiness: 0.1%Appeal to Nature0.0%This article: 0.0%Edward Lawrence: 0.0%FoxBusiness: 0.3%Composition/Division0.0%This article: 0.0%Edward Lawrence: 0.8%FoxBusiness: 2.4%Anecdotal0.0%This article: 0.0%Edward Lawrence: 0.0%FoxBusiness: 0.1%No True Scotsman0.0%This article: 11.2%Edward Lawrence: 0.7%FoxBusiness: 1.9%Ambiguity (Equivocation)11.2%This article: 0.0%Edward Lawrence: 0.0%FoxBusiness: 0.0%Gambler’s Fallacy0.0%This article: 0.0%Edward Lawrence: 0.0%FoxBusiness: 0.1%Middle Ground0.0%This article: 0.0%Edward Lawrence: 0.0%FoxBusiness: 0.1%Personal Incredulity0.0%This article: 0.0%Edward Lawrence: 0.2%FoxBusiness: 0.3%Special Pleading0.0%This article: 0.0%Edward Lawrence: 0.0%FoxBusiness: 0.2%Genetic Fallacy0.0%This article: 0.0%Edward Lawrence: 3.9%FoxBusiness: 1.8%Unattributed Quote0.0%This article: 0.0%Edward Lawrence: 2.6%FoxBusiness: 4.1%Biased Writer Voice0.0%This article: 0.0%Edward Lawrence: 0.0%FoxBusiness: 0.1%Politically Left Leaning Bias0.0%This article: 0.0%Edward Lawrence: 8.6%FoxBusiness: 2.1%Politically Right Leaning Bias0.0%This article: 0.0%Edward Lawrence: 1.0%FoxBusiness: 4.4%Attempt to Sell a Product or S…0.0%

358 words analyzed.

Speakers

No attributed speakers were identified in this analysis.

Loading…
Loading…
Loading…

Analysis

Hover over highlighted words in the article to view the associated bias or fallacy analysis.